RCS - Advanced Oncotherapy - Investor / Analyst Event Update

Advanced Oncotherapy

03/11/2022 15:20

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221103:nRSC2692Fa&default-theme=true

RNS Number : 2692F  Advanced Oncotherapy PLC  03 November 2022

REACH: non-regulatory announcement

3 November 2022

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Investor / Analyst Event Update

 

Advanced Oncotherapy (AIM: AVO), the developer of LIGHT, the next generation
proton therapy system for cancer treatment, announces that due to the high
number of requests to attend the event, as well as the impact of the rail
strikes planned next week affecting travel to/ from the Company's assembly
site at Daresbury on Tuesday, 8 November, the Company is scheduling an
additional investor/ analyst event on Tuesday, 22 November for those not able
to attend the one scheduled next week.

 

To register your interest in attending this additional event on Tuesday, 22
November, or the event on Tuesday, 8 November, please contact ir@avo-adam.com
(mailto:ir@avo-adam.com) . The events will be held in person and will also
include a tour of the site's technical area including the first operational
LIGHT system. Due to health and safety restrictions in the technical area of
the LIGHT system the total number of visitors is limited and therefore any
application to attend the event will be subsequently confirmed based on the
total number of registrations received.

 

The presentation will be available on the Company's website on 8 November
2022, the day of the first event.

 

For more information on LIGHT, please see this video
(https://www.youtube.com/watch?v=IoMEC7b83LQ&feature=emb_imp_woyt)
explaining the technology.

 

The full agenda for both events is as follows:

 

 Presentation                                         Time (GMT)

 Arrival at Daresbury                                 12:45

 Presentation by the Company's management including:  13:00 - 14:00
 Nicolas Serandour, Chief Executive Officer
 Prof. Steve Myers. Executive Chairman ADAM S.A.
 Ed Lee, Chief Operating Officer
 Moataz Karmalawy, Chief Commercial Officer
 Jonathan Farr, Chief Clinical Officer

 Tour of the technical area and LIGHT system          14:00 - 15:30

 Q&A                                                  15:30 - 16:30

 

- ENDS -

 

 

 Advanced Oncotherapy plc                                  www.avoplc.com (http://www.avoplc.com)
 Dr. Michael Sinclair, Executive Chairman                  Tel: +44 (0) 20 3617 8728
 Nicolas Serandour, CEO

 Allenby Capital Limited (Nomad and Joint Broker)
 Nick Athanas / Piers Shimwell (Corporate Finance)         Tel: +44 (0) 20 3328 5656

 Amrit Nahal / Matt Butlin (Sales and Corporate Broking)

 SI Capital Ltd (Joint Broker)
 Nick Emerson                                              Tel: +44 (0) 1483 413 500
 Jon Levinson                                              Tel: +44 (0) 20 3871 4066

 FTI Consulting (Financial PR & IR)                        advancedoncotherapy@fticonsulting.com
                                                           (mailto:advancedoncotherapy@fticonsulting.com)
 Simon Conway / Rob Winder                                 Tel: +44 (0) 20 3727 1000

 

Notes to Editors

 

About Advanced Oncotherapy Plc

 

Advanced Oncotherapy, a UK headquartered company with offices in London,
Geneva, The Netherlands and in the USA, is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced Oncotherapy's
team "ADAM," based in Geneva, focuses on the development of a proprietary
proton accelerator called, Linac Image Guided Hadron Technology (LIGHT).
LIGHT's compact configuration delivers proton beams in a way that facilitates
greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that
will enable them to treat cancer with innovative technology as well as
expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging
improvements in delivering proton therapy and actively seeks working
relationships with providers of these innovative technologies. Through these
relationships, the Company will remain the prime provider of an innovative and
cost-effective system for particle therapy with protons.

 

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUOAVRUOUARAA